*Clinical data conducted with Orsiro, Orsiro Mission’s predecessor device can be used to illustrate Orsiro Mission clinical data.
**BIOTRONIK data on file, status as per January 2020
Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies.
References:
1 Xience is a trademark or registered trademark of the Abbott Group of Companies.
2 Kandzari D et al. The Lancet. 2017, 390(10105).
3 Pilgrim et al. Biodegradable – versus durable-polymer drug-eluting stents for STEMI. Final 2-year outcomes of the BIOSTEMI trial. J Am Coll Cardiol. Cardiovasc Interven. 2021, doi: 10.1016/j.jcin.2020.12.011.
4 Kandzari D et al. J Am Coll Cardiol. Cardiovasc Interven. 2020, doi: 10.1016/j.jcin.2020.02.019.
5 Kandzari D presented at CRT 2022 – Late Breaking Clinical Trial February 27th, 2022, Late Breaking Trials: Session I
6 Kandzari et al, Supplement to: Kandzari DE, Mauri L, Koolen JJ et al. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularisation (BIOFLOW V): a randomised trial, JACC, 2017
7 Kandzari, BIOFLOW V – Comparison of ultrathin sirolimus eluting bioresorbable polymer with thin everolimus eluting durable polymer stents, Presented at ESC Congress, Barcelona, 2017
8 Pilgrim et al. Biodegradable – versus durable-polymer drug-eluting stents for STEMI. Final 2-year outcomes of the BIOSTEMI trial. J Am Coll Cardiol. Cardiovasc Interven. 2021, doi: 10.1016/j.jcin.2020.12.011
For indications please see Instructions For Use.
For more information, visit:
https://en.orsiro.com/